Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood coagulation changes after transcatheter atrial septal defect closure
ChiCTR-TRC-09000346Phase 4Completed
- Sponsor
- Xinqiao Hospital
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heparin, enoxaparin and aspirin in atrial septal defect (ASD) (3 arms), sponsored by Xinqiao Hospital. Primary endpoints: platelet activation, prothrombin activation and 1 more. Started Jan 2009; status: completed.
02
Drugs
heparinenoxaparinaspirin
03
Conditions
atrial septal defect (ASD)
Beyond the preview
Go deeper on ChiCTR-TRC-09000346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000346.